Select Publications
Journal articles
2024, 'Long-term prescribed opioid use after hospitalization or emergency department presentation among opioid naïve adults (2014–2020)—A population-based descriptive cohort study', British Journal of Clinical Pharmacology, 90, pp. 2111 - 2123, http://dx.doi.org/10.1111/bcp.16093
,2024, 'Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022', International Journal of Drug Policy, 123, http://dx.doi.org/10.1016/j.drugpo.2023.104255
,2023, 'Agreement of acute serious events recorded across datasets using linked Australian general practice, hospital, emergency department and death data: implications for research and surveillance', International Journal of Population Data Science, 8, http://dx.doi.org/10.23889/ijpds.v8i1.2118
,2022, 'Utilisation of pre-exposure prophylaxis (PrEP) for HIV prevention in the Australian general practice setting: a longitudinal observational study', Sexual Health, 19, pp. 101 - 111, http://dx.doi.org/10.1071/SH21207
,2022, 'Characteristics of patients aged 50-74 years with a request for an immunochemical faecal occult blood test in the Australian general practice setting', Australian Health Review, 46, pp. 222 - 232, http://dx.doi.org/10.1071/AH21129
,2022, 'A cluster randomized controlled trial of a MedicineInsight Educational Quality Improvement Programme to improve the diagnosis and treatment of chronic hepatitis C in general practice (the EQUIP-HEPC trial)', Journal of Viral Hepatitis, 29, pp. 135 - 146, http://dx.doi.org/10.1111/jvh.13629
,2022, 'Evaluating the accuracy of data extracted from electronic health records into MedicineInsight, a national Australian general practice database', International Journal of Population Data Science, 7, http://dx.doi.org/10.23889/IJPDS.V7I1.1713
,2021, 'Validity of algorithms for identifying five chronic conditions in MedicineInsight, an Australian national general practice database', BMC Health Services Research, 21, pp. 551, http://dx.doi.org/10.1186/s12913-021-06593-z
,2021, 'Patterns of real-world opioid prescribing in Australian general practice (2013-18)', Australian Journal of Primary Health, 27, pp. 416 - 424, http://dx.doi.org/10.1071/PY20270
,2021, 'The changing characteristics of patients with chronic hepatitis C prescribed direct acting antiviral medicines in general practice since listing of the medicines on the Australian Pharmaceutical Benefits Scheme', JGH Open, 5, pp. 813 - 819, http://dx.doi.org/10.1002/jgh3.12593
,2021, 'Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019', Human Vaccines & Immunotherapeutics, pp. 1 - 10, http://dx.doi.org/10.1080/21645515.2021.1923349
,2021, 'Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study', PLoS ONE, 16, pp. e0252458, http://dx.doi.org/10.1371/journal.pone.0252458
,2021, 'Exploring the physical health of patients with severe or long-term mental illness using routinely collected general practice data from MedicineInsight', Australian Journal of General Practice, 50, pp. 944 - 951, http://dx.doi.org/10.31128/AJGP-08-20-5563
,2021, 'Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study', BJGP Open, 5, pp. 1 - 10, http://dx.doi.org/10.3399/bjgpopen20X101120
,2020, 'Prevalence, incidence and management of atopic dermatitis in Australian general practice using routinely collected data from MedicineInsight', Australasian Journal of Dermatology, 61, pp. e319 - e327, http://dx.doi.org/10.1111/ajd.13268
,2020, 'Safety of live attenuated herpes zoster vaccine in adults 70–79 years: A self-controlled case series analysis using primary care data from Australia's MedicineInsight program', Vaccine, 38, pp. 3968 - 3979, http://dx.doi.org/10.1016/j.vaccine.2020.03.054
,2019, 'Data Resource Profile: MedicineInsight, an Australian national primary health care database', International Journal of Epidemiology, 48, pp. 1741 - 1741H, http://dx.doi.org/10.1093/ije/dyz147
,2018, 'Statin use in cancer survivors versus the general population: Cohort study using primary care data from the UK clinical practice research datalink', BMC Cancer, 18, pp. 1018, http://dx.doi.org/10.1186/s12885-018-4947-8
,2018, 'Insights into the management of chronic hepatitis C in primary care using MedicineInsight', Australian journal of general practice, 47, pp. 639 - 645, http://dx.doi.org/10.31128/AJGP-02-18-4482
,2014, 'Single-arm, observational study of the ease of use of a redesigned pen device to deliver recombinant human follicle-stimulating hormone (follitropin alfa) for assisted reproductive technology treatment', Patient Preference and Adherence, 8, pp. 813 - 826, http://dx.doi.org/10.2147/PPA.S58046
,Conference Papers
2021, 'Validity of algorithms for identifying five chronic conditions in MedicineInsight, Australian national primary care data', in INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, OXFORD UNIV PRESS, http://dx.doi.org/10.1093/ije/dyab168.270
,Conference Posters
2024, 'Long-term prescribed opioid use after hospitalisation or emergency department presentation among opioid-naïve adults in New South Wales (NSW), Australia (2014–2020)—a population-based cohort study', Wesley Conference Centre, Sydney NSW, presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024
,2024, 'Trends in prescription opioid analgesic use in Australia from 2015 to 2022: a national analysis using pharmaceutical claims and sales data', Wesley Conference Centre, Sydney NSW, presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024
,Conference Presentations
2024, 'Trends in prescription opioid analgesic use in Australia from 2015 to 2022: a national analysis using pharmaceutical claims and sales data', presented at 2024 NDARC Annual Research Symposium, Wesley Conference Centre, Sydney NSW, 20 September 2024, https://www.youtube.com/watch?v=vxBO7_cTwPU&t=330s
,Reports
2023, NDARC Technical Report: Real-world dosing intervals of long-acting buprenorphine for opioid agonist treatment., UNSW Sydney, Sydney, 345, http://dx.doi.org/10.26190/ayet-f348, https://ndarc.med.unsw.edu.au/resource/real-world-dosing-intervals-long-acting-buprenorphine-opioid-agonist-treatment
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in New South Wales, 2013-2022, UNSW Sydney, Sydney, 347, http://dx.doi.org/10.26190/rzmn-a864, https://ndarc.med.unsw.edu.au/resource/nsw-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in Queensland, 2013-2022, UNSW Sydney, Sydney, 349, http://dx.doi.org/10.26190/ybm1-3f83, https://ndarc.med.unsw.edu.au/resource/qld-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in South Australia, 2013-2022, UNSW Sydney, Sydney, 350, http://dx.doi.org/10.26190/y21d-yd24, https://ndarc.med.unsw.edu.au/resource/sa-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in Tasmania, 2013-2022, UNSW Sydney; National Drug and Alcohol Research Centre, Sydney, 351, http://dx.doi.org/10.26190/q6zj-fx75, https://ndarc.med.unsw.edu.au/resource/tas-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in the Australian Capital Territory, 2013-2022, UNSW Sydney; NDARC, Sydney, 346, http://dx.doi.org/10.26190/16m9-6z16, https://ndarc.med.unsw.edu.au/resource/ndarc-technical-reports-345-353
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in the Northern Territory, 2013-2022, UNSW Sydney, Sydney, 348, http://dx.doi.org/10.26190/mt8r-kd57, https://ndarc.med.unsw.edu.au/resource/nt-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in Victoria, 2013-2022, UNSW Sydney; National Drug and Alcohol Research Centre, Sydney, 352, http://dx.doi.org/10.26190/gjpp-py45, https://ndarc.med.unsw.edu.au/resource/vic-trends-use-opioid-agonist-treatment-australia-2013-2022
,2023, NDARC Technical Report: Trends in the use of Opioid Agonist Treatment in Western Australia, 2013-2022, UNSW Sydney; National Drug and Alcohol Research Centre, Sydney, 353, http://dx.doi.org/10.26190/ftbz-w461, https://ndarc.med.unsw.edu.au/resource/wa-trends-use-opioid-agonist-treatment-australia-2013-2022
,